Connor Iapoce

Initial real-world experience with ranibizumab biosimilar agents revealed no unexpected adverse outcomes across 16 retina centers, with similar efficacy to reference ranibizumab.

Results from the CT-P42 3.1 Study indicate the therapeutic equivalence of the aflibercept biosimilar, CT-P42, to the reference product in eyes with DME.

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 presentations from ASRS 2023. The discussion centered around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.

Granted to Ipsen, the breakthrough treatment reduces new, abnormal bone growth in people living with the ultra-rare bone disease.

Real-world data show the benefits of DEX implants prior to cataract surgery to achieve sufficient postoperative inflammation management and limit deterioration.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

Comparable efficacy, including of BCVA, CST, and fluid status between SB15 and reference aflibercept, was maintained up to Week 56 in nAMD eyes.

Health data from more than 50,000 adults revealed racial differences in cardiovascular mortality disappeared after adjusting for social risk factors.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our July 2023 month-in-review features a recap of conference coverage from the ASRS 41st Annual Scientific Meeting.

A new analysis suggests pseudomyopia was an independent risk factor for myopia development among school-aged children in China.

Results from the real-world AUSSIEDEX study suggest dexamethasone implant significantly improved anatomic outcomes at 52 weeks and showed no new safety concerns.

Large learning model-based platforms provide largely inaccurate responses to questions concerning vitreoretinal disease and remain inconsistent on repeat queries.

New study data indicate the growing knowledge of artificial intelligence chatbots in ophthalmology. We are joined by 3 study investigators to discuss what this could mean for the field overall and its impact on patient care.

A single dose of intravitreal bevacizumab in individuals undergoing trabeculectomy for progressing glaucoma shows improved postoperative outcomes at 12 months.

New 96-week data from PULSAR show patients treated with aflibercept 8 mg achieved good durability and maintained visual acuity gains from year 1 through year 2 of study.

Anatomic and visual improvements with high-dose aflibercept in CANDELA indicate a potential therapeutic benefit over aflibercept 2 mg, despite not achieving statistical significance.

Results from FARETINA-DME indicate a majority of eyes with DME began extending treatment intervals after 1-2 initial doses of faricimab.

Positive topline results from the phase 3 trial suggest once-daily OCS-01 met both primary trial endpoints for the treatment of inflammation and pain following cataract surgery.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.

Data from PK profiles and safety analyses of intravitreal sozinibercept suggest the promise of the drug in combination with standard anti-VEGF agents for AMD and DME.

Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development.

Presented at ASRS 2023, results from a posthoc analysis of YOSEMITE/RHINE suggest a potential anti-fibrotic effect of faricimab versus aflibercept in eyes with DME.

Presented at ASRS 2023, results from FARETINA-AMD suggest positive early treatment patterns and outcomes in patients with nAMD initiating faricimab treatment.

Presented at ASRS 2023, study data showed a single, in-office injection of RGX-314 gene therapy may have long-lasting improvements in diabetic retinopathy severity.

Presented at ASRS 2023, additional results from the Pagoda and Pavilion trials suggest a potential benefit of PDS for patients with DME and diabetic retinopathy.

Presented at ASRS 2023, results from the GALE extension study showed crossover to pegcetacoplan treatment from sham stabilized photoreceptor degeneration over 6 months.

A post hoc analysis of YOSEMITE/RHINE presented at ASRS 2023 suggests faricimab is linked to the faster absence of retinal fluid and fewer injections versus aflibercept in eyes with DME.

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

Presented at ASRS 2023, an analysis of the Portal trial suggests the efficacy and safety of PDS with ranibizumab was maintained over 5 years in patients with nAMD.